# of Displayed Technologies: 20 / 59

Applied Category Filter (Click To Remove): Clinical Area


Categories

DAT-CI knock-in mouse model carrying a modified dopamine transporter that maintains the transport function but resistant to cocaine inhibition and thus showing no rewarding cocaine effects
TS-058669 — A knock-in mouse model carrying a modified dopamine transporter that is resistant to cocaine inhibition and thus showing no rewarding cocaine effects.
Cocaine abuse has been an issue in the United States since the late 1980s. The highly addictive qualities along with the low cost ruined people’s lives and destroyed communities. Naloxone (marketed as Narcan) is highly effective but can only be used in the event of an overdose. Therefore, th…
  • College: College of Medicine (COM)
  • Inventors: Gu, Howard
  • Licensing Officer: Davis, Stewart

NET-CI knock-in mouse model with a modified norepinephrine transporter carrying triple mutations that maintains the transport function and makes the transporter protein resistant to cocaine and antidepressants
TS-058668 — A knock-in mouse model with a modified norepinephrine transporter carrying triple mutations that makes the transporter protein resistant to cocaine and antidepressants.
Cocaine abuse has been an issue in the United States since the late 1980s. Furthermore, antidepressants also quite dangerous, with nearly 14% of users (who have bipolar disorder) experiencing dependence. Naloxone (marketed as Narcan) is highly effective but can only be used in the event of an over…
  • College: College of Medicine (COM)
  • Inventors: Gu, Howard
  • Licensing Officer: Davis, Stewart

Rabbit Model for Duchenne Muscular Dystrophy
TS-058084 — A rabbit model has been created for Duchenne Muscular Dystrophy (DMD) that more closely resembles the effects experienced in humans while being more cost effective compared to larger animal models.
There has yet to be a DMD animal model that bridges the gap between cost effectiveness and scientific relevance. This new rabbit model does that. DMD is a lethal genetic disease characterized by progressive muscle weakness and muscle wasting. There are several animal models for DMD, includin…
  • College: College of Medicine (COM)
  • Inventors: Han, Renzhi
  • Licensing Officer: Davis, Stewart

Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the accumulation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by indu…
  • College: College of Medicine (COM)
  • Inventors: Li, Zihai
  • Licensing Officer: He, Panqing

An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
  • College: College of Medicine (COM)
  • Inventors: Bansal, Shyam; Gumina, Richard
  • Licensing Officer: He, Panqing

Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
  • College: College of Medicine (COM)
  • Inventors: Williams, Terence; Lee, Robert
  • Licensing Officer: He, Panqing

Reduction in Incidence and Severity of Acute Graft-Versus-Host Disease (aGVHD) via CRISPR-Cas9 Deletion of the miR-155 Host Gene (MIR155HG) in Primary Human T Cells
TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.
The Need More than 8,000 patients receive allo-HSCT annually in the US alone as a cure for hematologic malignancies and other primary bone marrow disorders. However, the major barrier for the success of allo-HSCT is the high incidence of aGVHD and its associated morbidity and mortality. Acute GVHD…
  • College: College of Medicine (COM)
  • Inventors: Ranganathan, Parvathi; Garzon, Ramiro
  • Licensing Officer: He, Panqing

A novel mouse model of spontaneous chronic lymphocytic leukemia
TS-055268 — The laboratory of Dr. Rosa Lapalombella in collaboration with Dr. James Blachly at The Ohio State University has developed a mouse model of spontaneous Chronic Lymphocytic Leukemia.
The Need Chronic lymphocytic leukemia (CLL) accounts for one quarter of new cases of leukemia. CLL is the most prevalent adult leukemia in Western countries and is characterized by a mature B-cell phenotype. Given the burden of this disease, a large pipeline of drugs for treatment are in progress…
  • College: College of Medicine (COM)
  • Inventors: Lapalombella, Rosa; Blachly, James; Byrd, John
  • Licensing Officer: Davis, Stewart

X-Ray Assistive Device for Standardizing the Knee Templating Process
TS-054471 — Knee templating is used as part of the pre-operative planning for knee replacement to determine the best fit for an implant. The current assistive devices used to determine fit are unreliable and inaccurate for proper patient fit. A new device is suggested to overcome these limitations.
Over 600,000 knee replacements are performed per year. As part of the pre-operative planning for surgery, x-ray images are taken to determine the proper fit for the implant. Even with the use of a calibration ball, this knee templating procedure remains inaccurate and unreliable for a number of re…
  • College: College of Engineering (COE)
  • Inventors: Ruegsegger, Mark; Aery, Dylan; Browske, Kimberly; Cantrell, Kaleb "Kaleb"; Reilman, Zach; Thew, Maddie
  • Licensing Officer: Zinn, Ryan

Therapeutic uses of the scavenging protein cocktail to treat plasma protein imbalances or depletion
TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.
Fluid replacement as part of resuscitation efforts in clinical care is a cornerstone of treatment especially in cases with severe trauma. The regular usage of these fluids in hospitals requires the mixture to be easily transported, easily stored and applicable across a wide variety of patients. To…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Davis, Stewart

Activation of human Argonaute3 (AGO3) using cityRNAs
TS-051298 — MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression post-transcriptionally. Their sequences differ, but their lengths fall within a range of ~20-23 nucleotides because the precursor miRNAs are processed by Dicer. Dicer cleaves long double-stranded RNA (dsRNA) molecules into s…
  • College: College of Arts & Sciences
  • Inventors: Nakanishi, Kotaro; Park, Mi Seul
  • Licensing Officer: Willson, Christopher

Mini-PCDH15 for treatment of deafness
TS-050433 — A gene therapy solution for Usher Syndrome Type 1F.
Mutations in PCDH15 cause Usher 1F, a recessive syndrome characterized by profound congenital deafness and absence of vestibular function, and progressive blindness beginning in the second decade. Because patients who lack hearing and balance rely on vision for communication and mobility, the late…
  • College: College of Arts & Sciences
  • Inventors: Sotomayor, Marcos
  • Licensing Officer: Willson, Christopher

SARS-CoV-2 Diagnostic Assay with Sensors of Immune Activation
TS-050296 — A sequencing-based diagnostic assay for SARS-CoV-2 with sensors of immune activation and the viral microbiota.
Diagnosis of SARS-CoV-2 infection, which is responsible for COVID-19 disease, is typically performed by molecular analysis of upper respiratory sampling (e.g. nasal swab). Transcriptional-mediated amplification (TMA) and quantitative (real-time) polymerase chain reaction (qPCR) using one or more v…
  • College: College of Medicine (COM)
  • Inventors: Jones, Daniel; Avenarius, Matthew; Tu, Huolin
  • Licensing Officer: Schworer, Adam

Smart Platform for Engineered Electroceutical Dressings (SPEEDs) Enables Better Wound Care
TS-050245 — An integrated platform with multiple sensing modalities to actively orchestrate antimicrobial activity and wound healing.
Wound healing and disinfection for chronic wounds presents significant hurdles within the medical industry. Current state of art is inadequate and adds a significant cost burden to the healthcare system with many health and life-quality challenges for patients. After the formation of an open wound…
  • College: College of Engineering (COE)
  • Inventors: Prakash, Shaurya; Heald, Rachel; Mohana Sundaram, Prashanth; Narayanan, Kavya; Stoodley, Paul; Subramaniam, Vishwanath; Vilku, Gurleen; Wilgus, Traci; Wozniak, Daniel
  • Licensing Officer: He, Panqing

Apoprotein manufacturing and methods for protein purification
TS-050238 — Methods of purifying proteins that can be used in various applications such as drug delivery, bioimaging and hemolysis treatment.
Novel protein and apoprotein purification strategies are valuable tools with a wide variety of medical and research applications. While there are existing techniques for protein and apoprotein purification, some of these have flaws such as the use of harsh denaturants, highly flammable solvents, l…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Davis, Stewart

Novel Natural Product Derivatives Targeting Chronic Diseases
TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity
The Need Metabolic disorders such as type 2 diabetes are a major health concern that have impacted hundreds of millions of adults worldwide. Current pharmaceutical therapies for type 2 diabetes have been associated with adverse reactions including weight gain and increased risk of infection, liver …
  • College: College of Pharmacy
  • Inventors: Carcache de Blanco, Esperanza; Anaya Eugenio, Gerardo David; Eggers, Nicole
  • Licensing Officer: He, Panqing

Targeting circular PCMTD1 in leukemias with p53 mutations
TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival of non-pediatric AML patients is only 30-40% in young patients (<60 years) and less than 10% in elderly AML patients (>60 years). This highlights …
  • College: College of Medicine (COM)
  • Inventors: Garzon, Ramiro; Papaioannou, Dimitrios
  • Licensing Officer: He, Panqing

Inhibition of DGAT for the treatment of cancer
TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…
  • College: College of Medicine (COM)
  • Inventors: Guo, Deliang
  • Licensing Officer: He, Panqing

An improved base editor (iABE-NG) for correcting genetic diseases such as Duchenne muscular dystrophy
TS-049505 — An engineered base editor (iABE-NG) that uses an SpCas9 variant, a shortened adenine deaminase domain with eliminated RNA off-target activity, and an intein split for packaging into an adeno-associated virus (AAV), resulting in gene mutation correction.
There are thousands of monogenic diseases that are lacking effective therapeutic treatments. The main bottleneck in developing effective treatment is the ability to effectively edit gene while controlling for the myriad of off-target effects that come with targeting the genome. Duchenne Muscular D…
  • College: College of Medicine (COM)
  • Inventors: Han, Renzhi; Gao, Yandi; Xu, Li
  • Licensing Officer: Davis, Stewart

Nras Mouse Melanoma Cell Lines
TS-049491 — Dr. Christin Burd's lab at The Ohio State University has developed a set of Nras-mutant mouse melanoma cell lines that can be used for preclinical tumor immunology and cancer biology studies.
Studies show that 15-30% of melanomas are Nras driven and 60% of melanomas are Braf driven. Dr. Christin Burd's lab at The Ohio State University has developed a set of Nras-mutant mouse melanoma cell lines that complement a set of Braf cell lines developed by Marcus Bosenberg at Yale Universit…
  • College: College of Medicine (COM)
  • Inventors: Burd, Christin; Murphy, Brandon
  • Licensing Officer: Davis, Stewart

Show More Technologies

Loading icon